November 2023 Medical News Summary

Why Physicians Don't Deprescribe Medicines; What to Know About Wegovy's Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug Related Content:

• As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging
• FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management
• Deciding When It's Better to Deprescribe Medicines Than to Continue Them